Functional Brands closes $8 million private placement and completes Nasdaq listing
Investing.com - Citizens raised its price target on Nuvation Bio Inc (NYSE:NUVB) to $8.00 from $6.00 on Tuesday, while maintaining a Market Outperform rating following the company’s third-quarter financial results. The new target aligns with the broader analyst consensus of Strong Buy, according to InvestingPro data, with the stock currently trading at $5.17, just 7% below its 52-week high of $5.55.
The research firm cited Nuvation Bio’s report of 204 new Ibtrozi starts in the third quarter of 2025, noting that the launch trajectory is exceeding expectations and already outpacing comparable ROS1 inhibitor launches in recent memory. This strong performance has contributed to the stock’s impressive 125.76% return over the past year.
Based on the strong performance of Ibtrozi, Citizens has increased its near-term projections for the biopharmaceutical company, leading to the higher price target.
The new $8.00 price target represents a $2.00 increase from the previous target of $6.00 and is derived from discounted cash flow analysis, according to Citizens.
Nuvation Bio, which focuses on developing novel therapeutics for oncology, maintains its Market Outperform rating from the research firm amid the positive sales momentum for its lead product. For investors seeking deeper analysis, InvestingPro offers 10 additional ProTips and a comprehensive Pro Research Report on NUVB, providing essential insights beyond standard financial metrics.
In other recent news, Nuvation Bio Inc. reported its third-quarter 2025 earnings, showcasing a substantial revenue beat. The company achieved an actual revenue of $13.1 million, significantly exceeding the forecasted $6.8 million, which marks a 92.94% surprise. Additionally, Nuvation Bio reported an earnings per share (EPS) of -$0.16, slightly better than the anticipated -$0.17. These results highlight the company’s performance in surpassing market expectations. The financial outcomes have contributed to a positive sentiment among investors. Analysts and market participants are closely monitoring these developments. Nuvation Bio’s recent performance has drawn attention from various investment firms. The company’s ability to exceed revenue forecasts underscores its current market position. These developments are part of the ongoing narrative surrounding Nuvation Bio’s financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.